Marc Raab, MD, PhD, discussed the MajesTEC-5 trial of teclistamab plus standard myeloma therapies in transplant-eligible ...

A four-drug regimen offers superior disease control and response depth in multiple myeloma compared to three-drug regimens ... until we learn if CAR-T or bi-specific T cell engagers can come to the ...

Anita D'Souza, MD, discussed the results from the MajesTEC-2 and TRIMM-2 trials in patients with multiple myeloma ... For MajesTEC-2, these were [patients with] myeloma who had received 1 to 3 prior ...

11 Most people with standard-risk multiple myeloma stay in remission for 2 to 3 years, although remission can last longer 11 Others may have early relapse, which happens during or shortly after their ...

What Is Refractory Multiple Myeloma? Multiple myeloma is a cancer that affects a type of white blood cell called a plasma cell, which helps your immune system fight infections. Refractory means ...

multiple myeloma (MM). The recommendation is specific to those who have received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal ...

and has already been approved in previously treated multiple myeloma patients. Moving the drug to the first line indication could unseat Darzalex, which is gaining a foothold in this patient group ...